Healthkart, owned by Intel-backed Bright Lifecare, has added $12m to its coffers thanks to Sequoia Capital and Kae Capital.

Bioniz has secured $13m in a round co-led by Takeda Ventures and David Pyott, who has been named chairman of the immuno-inflammatory disease drug developer.

Big Health, developer of a product that helps people combat insomnia, has been backed by Kaiser Permanente in its third funding round.

Just Biotherapeutics has raised $14m in series A2 funding, with Eli Lilly and Merck & Co returning after taking part in a $15m series A round in September.

The India-based conglomerate is aiming to raise an initial $15m for the fund, following the creation of a dedicated department to identify opportunities.

All Vtesse's existing series A investors, including Pfizer and Lundbeck, returned to provide a $17m extension that boosted the round's total to $42m.

Mitsui also plans to form strategic links between other regional portfolio companies and hospital operator Columbia Asia, an offshoot of US-based Columbia Pacific Management.

Providence Health & Service joined Excel Venture Management to fund precision oncology analysis company N-of-One's latest round, which will support sales and marketing.

Staidson Biopharmaceuticals has supported a $34m series C round for InflaRx, which is working on treatments for acute and chronic inflammatory conditions.